View : 552 Download: 0
Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)
- Title
- Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)
- Authors
- Jung S.-H.; Lee J.-J.; Kim J.S.; Min C.-K.; Kim K.; Choi Y.; Eom H.-S.; Joo Y.D.; Kim S.-H.; Kwak J.-Y.; Kang H.J.; Lee J.H.; Lee H.S.; Mun Y.-C.; Moon J.H.; Sohn S.K.; Park S.K.; Park Y.; Shin H.-J.; Yoon S.-S.; Korean Multiple Myeloma Working Party
- Ewha Authors
- 문영철
- SCOPUS Author ID
- 문영철
- Issue Date
- 2018
- Journal Title
- Biology of Blood and Marrow Transplantation
- ISSN
- 1083-8791
- Citation
- Biology of Blood and Marrow Transplantation vol. 24, no. 5, pp. 923 - 929
- Keywords
- Autologous transplantation; Intravenous busulfan; Melphalan; Multiple myeloma
- Publisher
- Elsevier Inc.
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m2) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9%) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0%, including 43.5% with a stringent complete response/complete response, 27.3% with very good partial response, and 23.2% with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3%) and stomatitis (15.2%). Three (3.2%) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression-free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable. ClinicalTrials.gov. number: NCT01923935 © 2018 The American Society for Blood and Marrow Transplantation
- DOI
- 10.1016/j.bbmt.2018.01.004
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML